Duchenne Research Fund
  • Home
  • Duchenne facts
  • Our story
  • Our projects
  • News
  • Get involved
    • Get involved
    • Gallery
  • Contact
  • Donate
Select Page

Catalysts Pharmaceuticals to distribute vamorolone in North America

22 Jun 2023

Santhera Pharmaceuticals, which manufacturers vamorolone – the steroid alternative which the DRF was involved in funding at the Phase 1 stage – has announced it has licensed vamorolone to Catalyst Pharmaceuticals in North America. Catalyst Pharmaceuticals...

Most recent:

  • Duchenne Care UK podcast series launched
  • Duchenne Care UK orthopaedic guideline recognised by NICE
  • Landmark day for Duchenne as Givinostat approved for use in England
  • Solid doses first patient on Phase 3 trial
  • Duchenne Care UK launches psychosocial guidelines

More about our projects:

administrative post award clinical post complementary current drug development early stage facility gene therapy past post project research standards of care

Jump to:

  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Donate
  • Contact Us
  • Get involved
  • Gallery
  • Our projects
  • Our story
  • Privacy
  • Home
  • Facebook
  • Twitter
  • Instagram
Copyright © 2026 The Duchenne Research Fund. Registered Charity No. 1119068. Website by Sheli Rodney